Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 7 14 21 versus TRI LO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 7 14 21 versus TRI LO LINYAH.
ORTHO-NOVUM 7/14-21 vs TRI-LO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
One tablet containing 0.5 mg norethindrone/0.035 mg ethinyl estradiol (white tablets) on days 1-14, then one tablet containing 1 mg norethindrone/0.035 mg ethinyl estradiol (peach tablets) on days 15-21, then no tablets for 7 days; repeated cycles.
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
None Documented
None Documented
Norethindrone: 10-12 hours (terminal), ethinyl estradiol: 13-27 hours (terminal); clinical context: steady state achieved within 5-7 days
Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment.
Renal: ~40% as glucuronide and sulfate conjugates; Fecal: ~20%; Biliary: minor
Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive